Jade Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months EndedMarch 31, 2026 | Three Months Ended March 31, 2025 | |
|---|---|---|
| Operating expenses: | ||
| Research and development(1) | $36,053 | $20,023 |
| General and administrative(2) | 7,392 | 3,361 |
| Total operating expenses | 43,445 | 23,384 |
| Loss from operations | (43,445) | (23,384) |
| Other income (expense): | ||
| Interest income | 3,102 | 615 |
| Change in fair value of Convertible Notes payable(3) | — | (15,400) |
| Other expense | (9) | — |
| Total other income (expense), net | 3,093 | (14,785) |
| Net loss before income tax expense | (40,352) | (38,169) |
| Income tax expense | (16) | — |
| Net loss | $(40,368) | $(38,169) |
| Other comprehensive income (loss): | ||
| Currency translation adjustment | 2 | — |
| Unrealized loss on investments | (473) | — |
| Comprehensive loss | $(40,839) | $(38,169) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.57) | $(12.10) |
| Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | $(573.44) | $— |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 57,777,165 | 3,155,500 |
| Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | 12,622 | — |
(1)Includes related party amounts of $4.3 million and $7.8 million for the three months ended March 31, 2026 and March 31, 2025, respectively (see Note 10).
(2)Includes related party amounts of $0.2 million and $0.1 million for the three months ended March 31, 2026 and March 31, 2025, respectively (see Note 10).
(3)Includesno related party amounts for the three months ended March 31, 2026 and $3.3 million for the three months ended March 31, 2025 (see Note 6).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.